News Feed Comments

J&JPRD submits an NDA for tapentadol ER tablets (News-Medical-Net)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets, an investigational oral analgesic for the management of moderate to severe chronic pain in patients 18 years of age or older.

Posted by Vyvanse In the News on at
Filed under Vyvanse News · Tagged with 18 Years, Amp, Chronic Pain, Drug Application, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Johnson Johnson, Jprd, Nda, Oral, Pharmaceutical Research

Speak Your Mind

Tell us what you're thinking...
and oh, if you want a pic to show with your comment, go get a gravatar!

Footer #1 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #2 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #3 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

Footer #4 Widget

This is an example of a widgeted area that you can place text to describe a particular product or service.
You can also use other WordPress widgets such as recent posts, recent comments, tag clouds, etc.

© 2010 VyvanseInfo.com · Streamline theme by StudioPress · Get a Blog · WordPress · Log in